This article is more than 5 years old. Information may no longer be current.

Baseline ocular characteristics improve patient selection for ocriplasmin treatment

Issue: August 25, 2018

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

David S. Boyer

VANCOUVER, British Columbia — Specific baseline ocular characteristics can help to identify patients with vitreomacular adhesion resolution who can benefit from ocriplasmin treatment, according to a speaker here.

This sub-analysis of the phase 4, multicenter, prospective Ocriplasmin Research to Better Inform Treatment (ORBIT) study evaluated the effect of baseline ocular patient characteristics on the resolution of vitreomacular adhesion (VMA) and vitreomacular traction (VMT) in patients receiving ocriplasmin.

“Patient selection based on baseline ocular characteristics really can help us identify patients who should do very well. Patients with phakic lens status, smaller areas of adhesion, full-thickness macular holes, and the absence of epitretinal membranes (ERM) will probably have a higher chance of success,” David S. Boyer, MD, said at the American Society of Retina Specialists meeting.

The ORBIT study included 480 patients with confirmed VMA/VMT treated with a single 0.125 mg intravitreal injection of ocriplasmin (Jetrea, ThromboGenics). Phakic patients had a much higher chance of resolution at 12 months, 65.9%, when compared with the resolution rate of 45.1% of pseudophakic patients, Boyer said.

Additionally, the presence of ERM at baseline significantly lowered VMA/VMT resolution, 43.2% of patients, compared with a resolution rate of 64.1% of patients with the absence of ERM at baseline. Patients with a VMA diameter of 500 µm or less at baseline experienced a higher VMA resolution rate than patients with a VMA diameter of greater than 500 µm, Boyer said.

Finally, 72% of patients with full-thickness macular holes experienced resolution at 12 months compared with a 54.7% resolution rate of patients without full-thickness macular holes at baseline, he said. – by Robert Linnehan

Reference: Boyer DS. Impact of baseline ocular characteristics on vitreomacular adhesion resolution with the ocriplasmin treatment: ORBIT Study. Presented at: American Society of Retina Specialists annual meeting; July 20-25, 2018; Vancouver.

Disclosure: Boyer reports he is a consultant for ThromboGenics.